Empagliflozin provides early clinical benefit in patients with heart failure with preserved ejection fraction, who face a 50% 6-month readmission and 20-30% 1-year mortality risk.
Absolute Event Rate: 0% vs 0%
Patients with chronic heart failure (HF) are at a high risk for adverse outcomes and once hospitalized, the risk for readmission is 20-25 at 1 month and 50% at 6 months, with a 1-year post-discharge mortality rate ranging between 20% and 30%.
Butler et al. (Wed,) reported a other. Empagliflozin provides early clinical benefit in patients with heart failure with preserved ejection fraction, who face a 50% 6-month readmission and 20-30% 1-year mortality risk.